Modern aspects of the treatment and prevention of diabetes type 2 in patients with metabolic syndrome

Cover Page

Abstract


Literature review is devoted to the most important medical-social problems of the XXI century - metabolic syndrome and diabetes mellitus type 2. Dirung the last decades prevalence of this pathology is steadily growing worldwide. Metabolic syndrome is associated with high risk of developing diabetes type 2, which is associated with early disability and high mortality from vascular complications. The wide spread of undiagnosed diabetes among persons of working age results in the need for early active detection of the disease in this group. Prophylaxis plays a huge role in the prevention of negative effects of diabetes. Since the major modifiable risk factors of its development are visceral obesity and a complex of its associated states (metabolic syndrome components), normalization of body weight preserves its significance as a measure of primary, secondary and tertiary prevention. In patients with diabetes not only carbohydrate metabolism requires correction, but also body mass, lipid profile, blood pressure, and hemostasis system, that should be considered when choosing a glucose-lowering drug. The article presents the results of nationwide epidemiological studies devoted to the evaluation of prevalence of metabolic syndrome and diabetes type 2 among the adult population. Current understanding of pathogenesis of metabolic syndrome and diabetes is discussed. Attention is paid to 2017 guidelines of the American diabetes Association for obesity management in terms of diabetes prevention, as well as medications that can be used for weight loss in metabolic syndrome. The new criteria for screening for diabetes type 2 are described, the main results of recent studies on cardiovascular safety of glucose-lowering drugs are presented.


O M Uryas’ev

Author for correspondence.
darya.solomatina.89@mail.ru
Ryazan State Medical University named after Academician I.P. Pavlov Ryazan, Russia

Z A Morgunova

darya.solomatina.89@mail.ru
City Clinical Hospital №11 Ryazan, Russia

D Yu Gorbunova

darya.solomatina.89@mail.ru
Ryazan State Medical University named after Academician I.P. Pavlov Ryazan, Russia

O N Shcherbakova

darya.solomatina.89@mail.ru
Medical and Sanitary Unit of the Ministry of Internal Affairs of Russia in the Ryazan Region Ryazan, Russia

A A Pyko

darya.solomatina.89@mail.ru
Medical and Sanitary Unit of the Ministry of Internal Affairs of Russia in the Ryazan Region Ryazan, Russia

  • Guh P., Zhang W., Bansback N. The incidence of comorbidities related to obesity and overweight: a systimatic review and meta-analysis. BMC Public Health. 2009; 9: 88. doi: 10.1186/1471-2458-9-88.
  • Sarwar N., Gao P., Seshasai S.R. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375 (9733): 2215-2222. doi: 10.1016/S0140-6736(10)60484-9.
  • Beckman J.A., Creager M.A., Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002; 287 (19): 2570-2581. doi: 10.1001/jama.287.19.2570.
  • Di Angelantonio E., Kaptoge S., Wormser D. et al. Assosiation of cardiometabolic multimorbidity. JAMA. 2015; 314 (1): 52-60. doi: 10.1001/jama.2015.7008.
  • DECODE Study Group. Glucose tollerance and mortality: comparison of WHO and American Diabetes Assiciation diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. Lancet. 1999; (354): 617-621. doi: 10.1016/S0140-6736(98)12131-1.
  • Федеральная служба государственной статистики. http://www.gks.ru/dbscripts/cbsd/dbinet.cgi (дата обращения: 04.02.2017).
  • Кантемирова Н.К., Заболотных И.И. Метаболический синдром: патогенез, клиническая картина, диагностика, медико-социальная экспертиза, реабилитация, лечение. СПб.: СПбМАПО. 2005; 120 с.
  • Reaven G.M. Role of insulin resistance in human disease. Diabetes.1988; 37 (12): 1595-1607. doi: 10.2337/diab.37.12.1595.
  • Reaven G.M. The metabolic syndrome: Time to get off the merry-go-round? J. Intern. Med. 2011; 269 (2): 127-136. doi: 10.1111/j.1365-2796.2010.02325.x.
  • Чазова И.Е. Диагностика и лечение метаболического синдрома: рекомендации экспертов Всероссийского общества кардиологов. М.: МИА. 2009; 6-10.
  • Сахарный диабет: диагностика, лечение, профилактика. Под ред. И.И. Дедова, М.В. Шестаковой. М.: МИА. 2011; 808 с.
  • Дедов И.И., Шестакова М.В., Галстян Г.Р. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой (7-й выпуск). Сахарный диабет. 2015; 18 (1S): 1-112. doi: 10.14341/DM7078.
  • Научно-организационный комитет проекта ЭССЕ-РФ. Эпидемиология сердечно-сосудистых заболеваний в различных регионах России (ЭССЕ-РФ). Обоснование и дизайн исследования. Профил. мед. 2013; (6): 25-34.
  • International Diabetes Federation. IDF diabetes atlas. 7th edition, 2015. http://www.diabetesatlas.org/across-the-globe.html (access date: 01.02.2017).
  • Государственный регистр больных сахарным диабетом. http://diaregistry.ru (дата обращения: 02.02.2017).
  • Дедов И.И., Шестакова М.В, Галстян Г.Р. Распространённость сахарного диабета 2-го типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016; 19 (2): 104-112. doi: 10.14341/DM2004116-17.
  • Смирнова О.М., Кононенко И.В. Инсулиты при сахарном диабете 2-го типа. Роль факторов врождённого иммунитета. В сб.: Β-клетка: секреция инсулина в норме и патологии. Выпуск 4. 2013; 60-81.
  • Könner A.S., Brüning J.C. Selective insulin and leptin resistance in metabolic disorders. Cell Metab. 2012; 16 (2): 144-152. doi: 10.1016/j.cmet.2012.07.004.
  • Larsen C.M., Faulenbach M., Vaag F. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. New Engl. J. Med. 2007; 356: 1517-1526. doi: 10.1056/NEJMoa065213.
  • Консенсус российских экспертов по проблеме метаболического синдрома в Российской Федерации: определение, диагностические критерии, первичная профилактика и лечение. Consil. Med. 2010; 12 (5): 5-11.
  • Loveman E., Frampton G., Shepherd J. et al. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. Health Technol. Assess. 2011; 15: 1-182. doi: 10.3310/hta15020.
  • Anderson J., Konz E., Frederich R., Wood C. Long-term weight-loss maintenance: a metaanalysis of US studies. Am. J. Clin. Nutr. 2001; 74: 579-584. PMID: 11684524.
  • American Diabetes Assosiation. Standards of medical care in diabetes-2017. Diabetes Care. 2017; 40 (Suppl 1): S57-S74.
  • Инструкция по медицинскому применению лекарственного препарата Саксенда® (раствор для подкожного введения, 6 мг/мл). Регистрационное удостоверение ЛП-003491 от 09.03.2016.
  • Mamputu J.C., Wiernsperger N.F., Renier G.A. Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab. 2003; 29 (6): 71-76. doi: 10.1016/S1262-3636(03)72790-6.
  • Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl. J. Med. 2002; 346 (5): 393-403. doi: 10.1056/NEJMoa012512.
  • Chiasson M., Gerstein H.C., Wang Y. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002; 359 (10): 2072-2077. doi: 10.1016/S0140-6736(02)08905-5.
  • Gerstein H.C., Yusuf S., Bosch J. Effect of rosiglitazone on the freqency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006; 368 (5): 1096-1105. doi: 10.1016/S0140-6736(06)69420-8.
  • Torgerson J.S., Hauptman J., Boldrin M.N. et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistatas an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004; (27): 155-161. doi: 10.2337/diacare.27.1.155.
  • Grundy S.M., Brewer H.P., Cleeman J.I. et al. Defenition of metabolic syndrome. Report of the National Heart, Lung and Blood Institute National Heart. American Heart Association conference of scientific issues related to definition. Circulation. 2004; 109 (3): 433-438. doi: 10.1161/01.CIR.0000111245.75752.C6.
  • FDA. Guidance for industry diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008; 2-4.
  • Marso S.P., Daniels G.H., Brown-Frandsen K. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New Engl. J. Med. 2016; 375: 1797-1799. doi: 10.1056/NEJMc1611289.
  • Zinman B., Wanner C., Lachin J.M. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl. J. Med. 2016; 374: 1092-1094. doi: 10.1056/NEJMc1600827.
  • Marso S.P., Bain S.C., Consoli A. et al. Semaglutide and cardiovascular outcomes in type 2 diabetes. New Engl. J. Med. 2016; 375: 1834-1844. doi: 10.1056/NEJMoa1607141.
  • Frias J.P., Guja C., Hardy E. et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016; 4 (12): 1004-1016. doi: 10.1016/S2213-8587(16)30267-4.

Views

Abstract - 157

PDF (Russian) - 107


© 2017 Uryas’ev O.M., Morgunova Z.A., Gorbunova D.Y., Shcherbakova O.N., Pyko A.A.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.